HUTCHMED (China) Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| H7T1.F | 300558.SZ | 6998.HK | 688321.SS | GUD.TO | 2096.HK | |
|---|---|---|---|---|---|---|
| Market cap | 2.22B | 20.76B | 3.11B | 9.47B | 1.11B | 28.55B |
| P/E (TTM) | 142.2 | 77.9 | 9.9 | 133.7 | 75.3 | 16.4 |
| Forward P/E | — | 29.2 | -1.9 | -107.0 | 43.5 | 12.1 |
| Price/book | 2.0 | 3.2 | 0.7 | 3.7 | 1.4 | 2.6 |
| Dividend yield | — | 0.31% | — | 0.28% | — | 1.92% |
| 1-year change | −9.77% | −12.57% | −45.69% | −31.78% | +86.16% | −16.51% |
| Today | +6.67% | +1.62% | +0.32% | +2.84% | +0.36% | +3.71% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All H7T1.F news ›Hutchmed China hails Orpathys acceptance for review in Japan and EU
Published on 11/02/2026 at 09:27 am EST (Alliance News) - Hutchmed China Ltd on Monday said regulatory filings for Orpathys, alias savolitinib, in combination with Tagrisso have been accepted for review in Japan and the EU. The Hong…
CICC Remains a Buy on HUTCHMED (China) (HCM)
CICC analyst maintained a Buy rating on HUTCHMED (China) yesterday and set a price target of HK$28.00. The company’s shares closed yesterday a... CICC analyst maintained a Buy rating on HUTCHMED (China) yesterday and set a price target of…
Hutchmed (China) Closes Licensing Deal with GSK for Drug Candidate HMPL-A830
Published on 10/20/2026 at 11:53 pm EDT Berenberg still a buyer of GSK, considering stock undervalued October 14, 2026 at 10:33 am EDT GSK plc: Priced for the storm, being built for thereafter GSK: shareholders urge company to step up…
Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
TradingView Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Rated "Moderate Buy" by Sell-Side Brokerages
Check Out Our Latest Stock Report on HUTCHMED HCM stock opened at $13.68 on Tuesday. The company's 50-day moving average price is $13.22 and its two-hundred day moving average price is $12.65. The company has a debt-to-equity ratio of…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com2
- marketbeat.com1
- markets.businessinsider.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.